Prospects and problems of gene therapy: An update

Expert Opinion on Emerging Drugs

Volumn 6, Issue 2, 2001, Pages 187-198

  Górecki, Dariusz C ^a  

^a UNIVERSITY OF PORTSMOUTH   (United Kingdom)

Author keywords

AAV; Adenovirus; Artificial chromosome; Gene therapy; Herpesvirus; Immunogenicity; Lentivirus; Plasmid; Retrovirus; Stem cell; Vector

Indexed keywords

GENE PRODUCT; RIBOZYME; VIRUS VECTOR;

ADENOVIRUS; ARTIFICIAL CHROMOSOME; CHIMERA; DNA MODIFICATION; DNA VECTOR; GENE DELIVERY SYSTEM; GENE EXPRESSION; GENE EXPRESSION REGULATION; GENE MUTATION; GENE TARGETING; GENE THERAPY; GENETIC DISORDER; GENOME; HERITABILITY; HERPES VIRUS; IMMUNE RESPONSE; IMMUNOGENICITY; LENTIVIRINAE; NONVIRAL GENE DELIVERY SYSTEM; PLASMID; RETROVIRUS; REVIEW; STEM CELL TRANSPLANTATION; TARGET CELL; TRANSGENE;

EID: 0035493724     PISSN: 14728214     EISSN: None     Source Type: Journal    
DOI: 10.1517/14728214.6.2.187     Document Type: Review

References (106)

1. Evidence for gene transfer and expression of factor IX in haemophilia B patients treated with an AAV vector
2. Gene therapy of human severe combined immunodeficiency (SCID)-X1 disease
3. A controlled trial of intratumoral ONYX-015, a selectively replicating adenovirus, in combination with cisplatin and 5-fluorouracil in patients with recurrent head and neck cancer
4. Researchers and regulators reflect on first gene therapy death
5. Adeno-associated virus vector carrying human minidystrophin genes effectively ameliorates muscular dystrophy in MDX mouse model
6. Gene therapy for rheumatoid arthritis
7. Ribozyme gene therapy: Applications for molecular medicine
8. Gene correction of the apolipoprotein (Apo) E2 phenotype to wild-type ApoE3 by in situ chimeraplasty
9. Clinical retrovital vector production: Step filtration using clinically approved filters improves titers
10. Vesicular stomatitis virus G glycoprotein pseudotyped retroviral vectors: Concentration to very high titer and efficient gene transfer into mammalian and nonmammalian cells
11. Retroviral vector targeting to human immunodeficiency virus type I-infected cells by receptor pseudotyping
12. Expression of a retrovirally transduced gene under control of an internal housekeeping gene promoter does not persist due to methylation and is restored partially by 5-azacytidine treatment
13. Dynamic analysis of proviral induction and de novo methylation: Implications for a histone deacetylase-independent, methylation density-dependent mechanism of transcriptional repression
14. Gene delivery systems for use in gene therapy: An overview of quality assurance and safety issues
15. Incorporation of decay-accelerating factor into the baculovirus envelope generates complement-resistant gene transfer vectors
16. Lentivirus and foamy virus vectors: Novel gene therapy tools
17. Filovirus-pseudotyped lentiviral vector can efficiently and stably transduce airway epithelia in vivo
18. In vivo gene therapy of metachromatic leukodystrophy by lentiviral vectors: Correction of neuropathology and protection against learning impairments in affected mice
19. Transduction of human CD34+ CD38- bone marrow and cord blood-derived SCID-repopulating cells with third-generation lentiviral vectors
20. Therapeutic haemoglobin synthesis in beta-thalassaemic mice expressing lentivirus-encoded human beta-globin
21. Self-inactivating lentivirus vector for safe and efficient in vivo gene delivery
22. Primate and feline lentivirus vector RNA packaging and propagation by heterologous lentivirus virions
23. Adenoviruses as gene-delivery vehicles
24. Biophysical targeting of adenovirus vectors for gene therapy
25. A new adenoviral vector: Replacement of all viral coding sequences with 2 kb of DNA independently expressing both full-length dystrophin and beta-galactosidase
26. Sustained high-level expression of full-length human factor VIII and restoration of clotting activity in hemophilic mice using a minimal adenovirus vector
27. An improved helper-dependent adenoviral vector allows persistent gene expression after intramuscular delivery and overcomes preexisting immunity to adenovirus
28. Cellular immune response to adenoviral vector infected cells does not require de novo viral gene expression: Implications for gene therapy
29. New helper cells and matched early region 1-deleted adenovirus vectors prevent generation of replication-competent adenoviruses
30. A cre-expressing cell line and an e1/e2a double-deleted virus for preparation of helper-dependent adenovirus vector
31. Instability of adenoviral vectors during transport and its implication for clinical studies
32. Tumor-specific gene expression in hepatic metastases by a replication-activated adenovirus vector
33. Roles of adeno-associated virus rep protein and human chromosome 19 in site-specific recombination
34. Trans-splicing vectors expand the utility of adeno-associated virus for gene therapy
35. Overcoming adeno-associated virus vector size limitation through viral DNA hererodimerizarion
36. Increasing the size of rAAV-mediated expression cassettes in vivo by intermolecular joining of two complementary vectors
37. Production of high-titer recombinant adeno-associated virus vectors in the absence of helper adenovirus
38. Improved adeno-associated virus vector production with transfection of a single helper adenovirus gene, E4orf6
39. Production and purification of recombinant adeno-associated virus
40. Gene therapy vectors based on adeno-associated virus type 1
41. Viral vectors for gene therapy in Parkinson's disease
42. Persistence and expression of the herpes simplex virus genome in the absence of immediate-early proteins
43. Antinociceptive effect of a genomic herpes simplex virus-based vector expressing human proenkephalin in rat dorsal root ganglion
44. Replicating herpes simplex virus vectors for cancer gene therapy
45. SV40-based gene therapy vectors: Turning an adversary into a friend
46. Poxvirus vectors: Orphaned and underappreciated
47. Efficient gene transfer to airway epithelium using recombinant Sendai virus
48. Evaluation of recombinant alphaviruses as vectors in gene therapy
49. Gene transfer to the nigrostriatal system by hybrid herpes simplex virus/adeno-associated virus amplicon vectors
50. Integrating adenovirus-adeno-associated virus hybrid vectors devoid of all viral genes
51. Polymer-coated adenovirus permits efficient retargeting and evades neutralising antibodies
52. 'Stealth' adenoviruses blunt cell-mediated and humoral immune responses against the virus and allow for significant gene expression upon readministration in the lung
53. Synthetic vectors for gene therapy
54. Key issues in non-viral gene delivery
55. Gene transfer by electroporation in vivo
56. Gene delivery: A single nuclear localization signal peptide is sufficient to carry DNA to the cell nucleus
57. Repeat administration of DNA/liposomes to the nasal epithelium of patients with cystic fibrosis
58. Systemic gene expression after intravenous DNA delivery into adult mice
59. Safety evaluation of hemagglutinating virus of Japan - Artificial viral envelope liposomes in nonhuman primates
60. Transgene expression in mouse airway epithelium by aerosol gene therapy with PEI-DNA complexes
61. Tracking the intracellular path of poly(ethylenimine)/DNA complexes for gene delivery
62. PEGylated DNA/transferrin-PEI complexes: Reduced interaction with blood components, extended circulation in blood and potential for systemic gene delivery
63. Systemic circulation of poly(L-lysine)/DNA vectors is influenced by polycation molecular weight and type of DNA: Differential circulation in mice and rats and the implications for human gene therapy
64. Particle formation by a conserved domain of the herpes simplex virus protein VP22 facilitating protein and nucleic acid delivery
65. Localized, direct plasmid gene delivery in vivo: Prolonged therapy results in reproducible tissue regeneration
66. Oral gene delivery with chitosan - DNA nanoparticles generates immunologic protection in a murine model of peanut allergy
67. Nonviral in vivo gene delivery into tumors using a novel low volume jet-injection technology
68. Interleukin 2 gene therapy for prostate cancer: Phase I clinical trial and basic biology
69. Constitutive expression of phVEGF165 after intramuscular gene transfer promotes collateral vessel development in patients with critical limb ischemia
70. Artificial chromosomes: Ideal vectors?
71. Novel generation of human satellite DNA-based artificial chromosomes in mammalian cells
72. Use of a human minichromosome as a cloning and expression vector for mammalian cells
73. Stable correction of a genetic deficiency in human cells by an episome carrying a 115 kb genomic transgene
74. An episomally maintained mdr1 gene for gene therapy
75. Transduction of dendritic cells by DNA viral vectors directs the immune response to transgene products in muscle fibers
76. VEGF gene delivery to myocardium: Deleterious effects of unregulated expression
77. Overexpression of {gamma}-sarcoglycan induces severe muscular dystrophy: Implications for the regulation of sarcoglycan assembly
78. Regulation of gene expression with synthetic dimerizers
79. Transcriptional activation by tetracyclines in mammalian cells
80. Ligand-inducible and liver-specific target gene expression in transgenic mice
81. Ecdysone-inducible gene expression in mammalian cells and transgenic mice
82. Adenovirus-mediated regulable target gene expression in vivo
83. Locus control region of the human cd2 gene in a lentivirus vector confers position-independent transgene expression
84. Remission in models of type I diabetes by gene therapy using a single-chain insulin analogue
85. Genomic DNA transfer with a high capacity adenovirus vector results in improved in vivo gene expression and decreased toxicity
86. Intravenous administration of an E1/E3-deleted adenoviral vector induces tolerance to factor IX in C57BL/6 mice
87. Cutting edge: Recombinant adenoviruses induce CD8 T cell responses to an inserted protein whose expression is limited to nonimmune cells
88. Chronic brain inflammation and persistent herpes simplex virus 1 thymidine kinase expression in survivors of syngeneic glioma treated by adenovirus-mediated gene therapy: Implications for clinical trials
89. Tissue-specific consequences of the anti-adenoviral immune response: Implications for cardiac transplants
90. Humoral immunity to adeno-associated virus type 2 vectors allowing administration to murine and nonhuman primate muscle
91. Immunostimulatory DNA sequences necessary for effective intradermal gene immunization
92. Intramuscular plasmid DNA injection can accelerate autoimmune responses
93. Immune responses to transgene-encoded proteins limit the stability of gene expression after injection of replication-defective adenovirus vectors
94. T-cell mediated rejection of gene-modified HIV-specific cytotoxic T lymphocytes in HIV-infected patients
95. Serum antibodies to the deleted dystrophin sequence after cardiac transplantation in a patient with Becker's muscular dystrophy
96. Recent patents in gene therapy
97. Gene therapy's web of corporate connections
98. Adeno-associated viral vector-mediated gene transfer results in long-term enzymatic and functional correction in multiple organs of fabry mice
99. Stable restoration of the sarcoglycan complex in dystrophic muscle perfused with histamine and a recombinant adeno-associated viral vector
100. Gene therapy restores vision in a canine model of childhood blindness
101. Peroral gene therapy of lactose intolerance using an adeno-associated virus vector
102. Long-term silencing of retroviral vectors is resistant to reversal by trichostatin A and 5-azacytidine
103. Purified hematopoietic stem cells can differentiate into hepatocytes in vivo
104. Intra arterial injection of muscle-derived CD34(+)Sca-1(+) stem cells restores dystrophin in MDX mice
105. Turning blood into brain: Cells bearing neuronal antigens generated in vivo from bone marrow
106. Multi-organ, multi-lineage engraftment by a single bone marrow-derived stem cell